Prasugrel or Ticagrelor in ST-Segment-Elevation Myocardial Infarction Patients With Diabetes Mellitus
- PMID: 28784829
- DOI: 10.1161/CIRCULATIONAHA.117.028745
Prasugrel or Ticagrelor in ST-Segment-Elevation Myocardial Infarction Patients With Diabetes Mellitus
Keywords: morphine cloride; myocardial infarction; platelet antagonists; platelet function test; prasugrel hydrochloride; ticagrelor.
Similar articles
-
Efficacy of prasugrel administration immediately after percutaneous coronary intervention in ST-elevation myocardial infarction.Thromb Haemost. 2017 Jan 5;117(1):99-104. doi: 10.1160/TH16-07-0569. Epub 2016 Oct 13. Thromb Haemost. 2017. PMID: 27734075
-
Time-dependent benefits of pre-treatment with new oral P2Y12 -inhibitors in patients addressed to primary PCI for acute ST-elevation myocardial infarction.Catheter Cardiovasc Interv. 2019 Mar 1;93(4):592-601. doi: 10.1002/ccd.27863. Epub 2018 Sep 30. Catheter Cardiovasc Interv. 2019. PMID: 30269413
-
Strategies to optimize initial P2Y12 inhibitor therapy in STEMI patients.Cardiovasc Revasc Med. 2025 Feb;71:43-49. doi: 10.1016/j.carrev.2024.09.012. Epub 2024 Sep 25. Cardiovasc Revasc Med. 2025. PMID: 39343662 Review.
-
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.Circulation. 2019 Apr 2;139(14):1661-1670. doi: 10.1161/CIRCULATIONAHA.118.038317. Circulation. 2019. PMID: 30630341 Clinical Trial.
-
Effect of ticagrelor versus prasugrel on platelet reactivity: a meta-analysis.Coron Artery Dis. 2017 Nov;28(7):597-604. doi: 10.1097/MCA.0000000000000541. Coron Artery Dis. 2017. PMID: 28968313 Review.
Cited by
-
The Role of Ranolazine for the Treatment of Residual Angina beyond the Percutaneous Coronary Revascularization.J Clin Med. 2020 Jul 4;9(7):2110. doi: 10.3390/jcm9072110. J Clin Med. 2020. PMID: 32635532 Free PMC article.
-
Myocardial Ischemia and Diabetes Mellitus: Role of Oxidative Stress in the Connection between Cardiac Metabolism and Coronary Blood Flow.J Diabetes Res. 2019 Apr 4;2019:9489826. doi: 10.1155/2019/9489826. eCollection 2019. J Diabetes Res. 2019. PMID: 31089475 Free PMC article. Review.
-
Hepatocyte growth factor intervention to reduce myocardial injury and improve cardiac function on diabetic myocardial infarction rats.Eur J Histochem. 2020 Jul 30;64(s2):3142. doi: 10.4081/ejh.2020.3142. Eur J Histochem. 2020. PMID: 32909423 Free PMC article.
-
Analysis of Ticagrelor's Cardio-protective Effects on Patients with ST-segment Elevation Acute Coronary Syndrome Accompanied with Diabetes.Open Med (Wars). 2019 Feb 20;14:234-240. doi: 10.1515/med-2019-0017. eCollection 2019. Open Med (Wars). 2019. PMID: 30847400 Free PMC article.
-
Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials.Cardiovasc Drugs Ther. 2021 Jun;35(3):561-574. doi: 10.1007/s10557-020-07056-z. Epub 2020 Aug 20. Cardiovasc Drugs Ther. 2021. PMID: 32816142
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical